Wegovy vs Zepbound: Choosing a Weight Treatment

These are label distinctions, with full eligibility criteria for each use. Cardiovascular disease, liver disease, or diagnosed sleep apnea can make an additional indication relevant. Discuss that diagnosis with the clinician managing it. Weight change alone cannot establish that another condition has resolved.

In SURMOUNT-5, adults with obesity and without type 2 diabetes received weekly tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg for seventy-two weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. The trial was randomized and open-label.

The result favors tirzepatide at those studied doses on average. It does not compare Zepbound with Wegovy tablets or the newer 7.2 mg injection. It also cannot predict one person's response. Digestive adverse effects were common in both groups, particularly during escalation.

Wegovy tablets require an empty stomach in the morning, up to four ounces of water, and a thirty-minute wait before food, other drinks, or oral medicines. Weekly injections can be taken with or without food. If mornings involve other medicines or an unpredictable schedule, discuss how oral treatment would fit.

Injection presentations vary. Confirm the exact device or vial and get training for it. Both products start at low doses and increase gradually. Their milligram doses are not equivalent, and missed-dose rules differ. A switch needs instructions for timing and the new starting dose.

Tirzepatide can reduce the effectiveness of oral hormonal contraception during initiation and escalation. Its label advises a nonoral method or added barrier contraception for four weeks after starting and each increase. Semaglutide has a two-month discontinuation interval before a planned pregnancy. Pregnancy plans belong in the initial discussion.

• Ask the insurer about the exact brand, formulation, diagnosis, and prior authorization.
• Request the continuing-dose price after any introductory offer ends.
• Confirm what follow-up and dietary support are included.
• Agree what happens if side effects, pregnancy plans, or payment require an interruption.

Both medicines are contraindicated with personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity. Severe gastroparesis, pancreatitis, gallbladder disease, diabetic eye disease, and other medicines need review. Choosing the product with the larger trial average does not remove those requirements.

If you already take one, describe its benefit and adverse effects before considering a change. Do not combine Wegovy and Zepbound or overlap doses on your own. The prescribing team should coordinate any transition and continuing monitoring.